Kenya - English - Pharmacy and Poisons Board

cipla quality chemical industries limited plot 1 - 7, 1st ring road, luzira industrial - dolutegravir sodium, lamivudine and tenofovir… - tablet - dolutegravir sodium 50mg, lamivudine 300mg and… - direct acting antivirals

Kenya - English - Pharmacy and Poisons Board

cipla limited cipla house, peninsula business park, ganpatrao - dolutegravir (as sodium) , lamivudine and… - film-coated tablet - dolutegravir (as sodium): 50 mg , lamivudine: 300… - lamivudine and tenofovir disoproxil

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

macleods pharmaceuticals limited, india - dolutegravir sodium, lamivudine , tenofovovir disoproxil fumarate - oral tablet - dolutegravir 50mg, lamivudine 300mg and tenofovir disoproxil fumerate 300mg

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - lamivudine, quantity: 300 mg; dolutegravir sodium, quantity: 52.6 mg (equivalent: dolutegravir, qty 50 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate type a; povidone; mannitol; titanium dioxide; microcrystalline cellulose; sodium stearylfumarate; magnesium stearate; hypromellose; macrogol 400 - dovato (a fixed dose combination of dolutegravir and lamivudine) is indicated for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adults and adolescents (from 12 years of age weighing at least 40kg): ? in antiretroviral treatment-na?ve patients with no antiretroviral treatment history who have no known or suspected resistance to either antiretroviral component; or ? to replace the current antiretroviral regimen in those who are virologically suppressed (hiv-1 rna less than 50 copies per ml) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to the integrase inhibitor class or lamivudine (see section 5.1 pharmacodynamic properties, clinical trials).

Kenya - English - Pharmacy and Poisons Board

cipla limited cipla house, peninsula business park, ganpatrao - dolutegravir sodium and lamivudine - tablet - 50 mg of dolutegravir (equivalent to 52.6 mg… - antivirals for systemic use: combinations of

United States - English - NLM (National Library of Medicine)

viiv healthcare company - dolutegravir sodium (unii: 1q1v9v5wyq) (dolutegravir - unii:dko1w9h7m1), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - dovato is indicated as a complete regimen for the treatment of hiv-1 infection in adults with no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (hiv-1 rna less than 50 copies per ml) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of dovato. dovato is contraindicated in patients: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to dovato during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1‑800‑258‑4263. risk summary data from an ongoing birth outcome surveillance study have identified an increased risk of neural tube defects when dolutegravir, a component of dovato, is administered at the time of conception. as defects related to closure of the neural tube occur from concepti

Kenya - English - Pharmacy and Poisons Board

dolutegravir sodium - film-coated tablet - dolutegravir sodium tablet for oral suspension… - dolutegravir

United States - English - NLM (National Library of Medicine)

viiv healthcare company - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), dolutegravir sodium (unii: 1q1v9v5wyq) (dolutegravir - unii:dko1w9h7m1), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - abacavir 600 mg - triumeq and triumeq pd are indicated for the treatment of hiv-1 infection in adults and in pediatric patients aged at least 3 months and weighing at least 6 kg. limitations of use: triumeq and triumeq pd alone are not recommended in patients with resistance‑associated integrase substitutions or clinically suspected integrase strand transfer inhibitor (insti) resistance because the dose of dolutegravir in triumeq and triumeq pd is insufficient in these subpopulations. see full prescribing information for tivicay (dolutegravir). triumeq and triumeq pd are contraindicated in patients: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to triumeq during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1‑800‑258‑4263. risk summary data from an ongoing birth outcome surveillance study has identified an increased risk of neural tube defects when dolutegravir, a componen

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

strides pharma science limited, india - dolutegravir sodium, lamivudine , tenofovovir disoproxil fumarate - tablets - 50/300/300 mg

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

strides pharma science limited, india - dolutegravir sodium, lamivudine , tenofovovir disoproxil fumarate - tablets - 50/300/300